We recently compiled a list of the Why These 24 Stocks Are Skyrocketing. In this article, we are going to take a look at where Chimerix, Inc. (NASDAQ:CMRX) stands against the other stocks. One of the ...

Chimerix meets financial expectations during Q2, 2023 earnings call. Investment thesis for Chimerix focuses on its ONC201 study expected to read out in 2026. Company has high risk of loss despite ...

-Transaction represents total cash consideration of approximately $935 million, or $8.55 per share- DUBLIN and DURHAM, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ...

Chimerix’s first approved drug had several high-profile setbacks and ended up with a much narrower regulatory nod than initially hoped. Now the company is selling rights to that drug to Emergent ...

Investors are furious about management's plan to sell its most valuable asset in order to chase a lackluster oncology program. Under the terms of the agreement, Chimerix will receive $225 million when ...

On Monday, Chimerix (NASDAQ:CMRX) announced that, following extensive dialogue with the FDA, the company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for ...

Shares of Chimerix Inc. shot up 14.4% in premarket trading Monday, after the biopharmaceutical company said it will sell exclusive rights to its smallpox treatment, including Tembexa, to Emergent ...

DURHAM, N.C., June 24, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients ...

Chimerix, a biopharmaceutical company, announced that the New Drug Application (NDA) for its drug Dordaviprone, aimed at treating recurrent H3 K27M-mutant diffuse glioma, is under review with a ...